Clinical trial
The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study
NCT00446862 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00446862 |
|---|---|
| Title | The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study |
| Official title | Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study |
| Acronym | FAACET |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Status | Completed |
| Study type | Observational |
| Conditions | Fabry Disease, Proteinuria |
| Intervention type | Drug |
| Interventions | enalapril and other angiotensin converting enzyme inhibitors, losartan and other angiotensin receptor blockers |
| Enrollment | 36 |
| Start date | Mar 1, 2007 |
| Primary completion | Jun 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Mar 13, 2007 |
| Last update posted | Nov 19, 2013 |
| Countries | Slovenia, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: